Bio-IT World October 23, 2024
There is much we still don’t know about the relationship between immune cells and cancer cells and how they interact and influence each other over the course of immune activating cancer therapies. Researchers at Cleveland Clinic are exploring these relationships and reported their results last month in Nature Medicine (DOI: https://doi.org/10.1038/s41591-024-03240-y).
Why Neoantigens?
“A lot of patients still don’t respond to immunotherapy,” says Tyler Alban, PhD, co-first author of the study. To understand how tumors are recognized and altered by immune systems in response to immunotherapy, Alban and his colleagues at Cleveland Clinic conducted a study with Bristol Myers Squibb.
They started their search at neoantigens. In order for...